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Background: Aberrant expression of microRNA-148a (miR-148a) has been reported in several types of malignancies.
However, its expression and clinicopathological significance in hepatocellular carcinoma (HCC) has not been entirely
clarified. Our objective was to investigate the clinicopathological contribution of the miR-148a expression in HCC
formalin-fixed paraffin-embedded (FFPE) tissues.
Methods: Eighty-nine HCC and their para-cancerous liver tissues were recruited. Total mRNA including miRNA
was isolated and miR-148a expression was determined by using real time RT-qPCR. Furthermore, the relationship
between the miR-148a level and clinicopathological features was explored.
Results: Significantly lower miR-148a expression in HCC tissues was observed than that in adjacent noncancerous
hepatic tissues. miR-148a expression was also correlated to clinical TNM stage, metastasis, status of capsular infiltration
and numbers of tumor nodes.
Conclusions: Underexpression of miR-148a might be associated with HCC tumorigenesis and deterioration of HCC.
miR-148a might act as a suppressor miRNA of HCC and it therefore has a potential role in prognosis of HCC patients.
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Hepatocellular carcinoma (HCC) is ranked as the sixth
most frequent cancer and the third leading cause of
cancer-related deaths globally [1,2]. In 2012, 782,000
new cases and 746,000 deaths from HCC occurred in
the whole world. The burden of the disease is the
highest in Eastern Asia, sub-Saharan Africa, and
Melanesia with the endemic infection of hepatitis B virus
(HBV). In the meantime, in Japan, United States, and
Europe, hepatitis C virus (HCV) infection is predomin-
ant, and consequently, it has become the key risk factor
for contracting HCC in these regions [3-7]. Although
the improvement of molecular biology has led to the
identification of new tumor markers that play vital roles
in the treatment and prognosis of HCC, more tumor
markers are still required for effective early diagnosis
and monitoring of the curative effect of HCC [8-15].* Correspondence: chen_gang_triones@163.com
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unless otherwise stated.MicroRNAs, a major class of small non-coding RNAs,
are well-conserved very small RNA molecules (20 to 22
nucleotides) that can negatively modulate gene expres-
sion post-transcriptionally. Accumulating evidence over
the past decades highlights the significance of micro-
RNAs as vital regulators of many essential physiological
processes such as cell proliferation, differentiation, apop-
tosis, and embryonic development [16]. Dysregulation of
microRNA expression has also been inferred in many
diseases as well as in cancers [17-21]. Extensive profiling
studies over recent years have shown that a variety of
miRNAs are abnormally expressed in HCC [22,23].
Among all the HCC-related miRNAs, miR-148a has
been reported to be significantly reduced in HCC tissues,
compared with normal livers [24,25]. However, the rela-
tionship between miR-148a level and the clinicopathologi-
cal parameters of HCC remains obscure. In the current
study, we therefore investigated the expression of miRNA-
148a in HCC and their matched adjacent noncancerous
liver tissues in formalin-fixed paraffin-embedded (FFPE)
surgically resected samples. Furthermore, we studied the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Relationship between the expression of miR-148a
and clinicopathological features in hepatocellular
carcinoma (HCC) xsÞð
Clinicopathological features n MiR-148a relevant expression
2-△cq t P




89 1.44 ± 0.61
Age ≥ 50 43 0.83 ± 0.49 −0.727 0.469
< 50 46 0.91 ± 0.51
Gender Male 72 0.88 ± 0.50 0.392 0.696
Female 17 0.83 ± 0.53
Differentiation Well 6 0.88 ± 0.40 F = 0.531a 0.590
Moderately 57 0.91 ± 0.52
Poorly 26 0.79 ± 0.48
Clinical TNM
stage
I to II 19 1.17 ± 0.58 3.106 0.003
III to IV 70 0.79 ± 0.45
Metastasis Yes 46 0.74 ± 0.51 −2.537 0.013
No 43 1.00 ± 0.46
With cirrhosis Yes 43 0.86 ± 0.52 −0.143 0.886
No 46 0.88 ± 0.48
AFP (μg/L) ≥ 400 35 0.90 ± 0.51 −0.015 0.988
< 400 38 0.90 ± 0.49
Portal vein tumor
embolus
Yes 29 0.76 ± 0.53 −1.400 0.165






48 0.76 ± 0.49 −2.308 0.023
No capsular
infiltration
41 1.00 ± 0.49
Tumor nodes Multiple 40 0.75 ± 0.47 −2.015 0.047
Single 49 0.96 ± 0.51
Tumor diameter
(cm)
≥ 5 73 0.91 ± 0.51 1.515 0.133
< 5 15 0.70 ± 0.46
Vaso-invasion Yes 32 0.79 ± 0.53 −1.116 0.267
No 56 0.92 ± 0.49
HBV infection Yes 73 0.84 ± 0.51 −1.347 0.181
No 16 1.02 ± 0.45
HCV infection Yes 29 0.94 ± 0.51 0.912 0.364
No 60 0.84 ± 0.50
ΔPaired t-student test was performed.
aOne-way analysis of variance (ANOVA) test was performed.
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pathological characteristics of HCC.
Methods
Tissue samples
This retrospective study included 89 cases of HCCs and
their paired paraneoplastic liver FFPE tissues. The age of
the HCC patients ranged from 29 to 82 years old, with a
mean age of 52 years. Clinicopathological information
extracted from medical records has been summarized in
Table 1. Adjacent noncancerous liver tissues were at
least 2 cm away from the tumor node. All cases were
initial hepatectomies without treatment and from hepa-
tectomies performed in the First Affiliated Hospital of
Guangxi Medical University, PR China between March
2010 and December 2011. The study protocol was ap-
proved by the Ethical Committee of the First Affiliated
Hospital of Guangxi Medical University. Written in-
formed consent was obtained from the patients and cli-
nicians for the usage of the samples for research. All
samples were reviewed and diagnosed by two independ-
ent pathologists.
RT-qPCR
Total RNA including miRNA was isolated from tumor
sections using the miRNeasy FFPE Kit (QIAGEN, KJ
Venlo, Netherlands) according to our previous reports
[26-28]. RNA concentrations were determined by Nano-
drop 2000 (Wilmington, DE , USA). A combination of
RUN6B and RUN48 was the housekeeping genes for de-
tection of miR-148a expression [27,28]. The primers for
miR-148a, RNU6B and RNU48 were included in Taq-
Man® MicroRNA Assays (4427975, Applied Biosystems,
Life Technologies Grand Island, NY, USA). The reverse
primers were also used for reverse transcription with Taq-
Man® MicroRNA Reverse Transcription Kit (4366596,
Applied Biosystems, Life Technologies Grand Island,
NY, USA) in a total volume of 10 μl. Real time RT-
qPCR for miRNA was performed with Applied Biosys-
tems PCR7900. The miR-148a abundance in each sample
was normalized to its references. The expression of miR-
148a in the FFPE experiments was calculated with the for-
mula 2-Δcq [26-29].
Statistical analysis
SPSS 20.0 (Munich, Germany) was performed for statis-
tical analysis. Results were representative of three inde-
pendent experiments. Values were presented as the
mean ± standard deviation (SD). Student’s paired or un-
paired t-test was used to analyze significance between
paired or unpaired groups. One-way analysis of variance
(ANOVA) test was used to analyze significance between
groups of various differentiations. Correlations were cal-
culated by Spearman’s method. A receiver operatorcharacteristic curve (ROC) was employed to identify the
diagnostic value. The relationship between miR-148a
and recurrence was analyzed by using the Kaplan-Meier
survival method. Statistical significance was determined
at a P < 0.05 level.
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Significantly lower expression of miR-148a in the HCC
tissues was detected than that in the adjacent noncan-
cerous hepatic tissues (Table 1, Figure 1). Furthermore,
the ROC curve was performed to identify the diagnostic
value of miR-148a level in HCC. The area under the
curve (AUC) of miR-148a was 0.761 (95% CI 0.692 to
0.830, P < 0.001). The cut-off value for miR-148a was the
median 2-Δcq 0.87. The sensitivity and specificity were
76.3% and 50.6%, respectively (Figure 2). With regard to
clinical TNM stages, miR-148a expression in early stages
(I and II) was remarkably higher than that in advanced
stages (III and IV). Lower levels of miR-148a were found
in HCC patients with metastasis, without capsular or
with capsular infiltration and multiple tumor nodes, in
comparison with patients of corresponding traits. In
addition, according to Spearman's correlation, negative
correlations were found between miR-148a expression
and several clinicopathological parameters, including
TNM stages, metastasis and the status of capsular infil-
tration. However, there was no association between miR-
148a expression and other clinicopathological features,
for instance, age, histological differentiation grades, cir-
rhosis, plasma alpha-fetoprotein (AFP) concentrations,
HBV, HCV, vaso-invasion, portal vein tumor embolus or
tumor size. Sixty-one among 76 patients were followed
up and time-to-recurrence was collected. Time-to-
recurrence for all 61 cases was 57.84 ± 3.03 weeks. The
patients with high expression of miR-148a (higher than
the median level) had a longer time-to-recurrence in
comparison to those with low expression (61.47 ± 3.45
versus 50.56 ± 4.15), however, the difference was not sig-
nificant (P = 0.238, Figure 1). Additionally, we per-
formed the univariate analysis and results showed that
miR-148a, as well as other parameters, was not a pre-
dictor for the recurrence of HCC in the current study
(data not shown).
Discussion
Most recently, miR-148a expression was reported by
Gailhouste et al. to be frequently down-regulated in
mouse and human HCC cell lines, as well as in biopsies
of HCC patients [25]. Concurrently, consistent de-
creased expression of miR-148a in HCC tissues was
found by Zhang et al. [24], as compared with normal
livers. Both of the aforementioned studies used normal
liver tissues as controls. Gailhouste et al. [25] found that
miR-148a expression was reduced by more than 5-fold
in HCC biopsies, relative to the normal liver group
(median, 0.293 and 1.674, respectively). In the present
study, accordant underexpression of miR-148a in HCC
tissues was also observed, in comparison with the corre-
sponding adjacent liver tissues in the same patients.
Furthermore, the ROC curve indicates a moderatediagnostic value of miR-148a in HCC with the AUC as
0.761. Besides, lower expression of miR-148a was also
detected in several HCC cell lines (HepG2, HepB3,
SNU449 and SMMC7211), than the normal hepatic cell
line LO2 (data not shown). The results of our study, to-
gether with those reported previously [24] [25], indicate
that miR-148a plays a critical role as a tumor suppressor
miRNA in hepatocarcinogenesis. However, the average
fold change of miR-148a level varied in comparison to
Gailhouste et al. [25] (1.655 versus 5.713). The different
controls used by Gailhouste et al. [25] and our group
(healthy liver tissues versus corresponding noncancerous
liver tissues) may partially explain the disparity. It might be
that the miR-148a expression is lower in noncancerous liver
tissue of HCC patients than in liver tissue of healthy con-
trols. It might also be of interest to investigate the dynamic
change of miR-148a expression in the hepatocarcinogenesis
and progression of HCC. For instance, a comparison of the
miR-148a levels in normal liver, cirrhotic tissue, adjacent
noncancerous liver, hepatic adenoma, atypical hyperplasia,
and HCC tissues would be worthwhile exploring.
MiRNAs can be identified in serum and plasma in an
extraordinarily stable form, which leads to the possibil-
ity to determine the expression of miRNAs in blood
samples [30,31]. The serum level of miR-148a was de-
tected in colorectal cancer and could be regarded as a
marker to predict early tumor recurrence [32]. miR-
148a was determined in the serum of other malignan-
cies, such as breast cancer, gastric cancer and multiple
myeloma [33-35]. Gailhouste et al. [25] also assessed
the value of circulating miR-148a as a noninvasive HCC
biomarker in blood serum in HCC. However, only 11
cases with HCV infection were included. The signifi-
cance of circulating miR-148a in the early diagnosis
and prognosis prediction of HCC remains unclarified.
Further studies will be required to explore the alter-
ation of miR-148a expression in serum and in tissue, as
well as to investigate the relationship between serum
miR-148a level and the clinicopathological parameters
of HCC patients.
Concerning the relationship between miR-148a ex-
pression and clinicopathological parameters, Yan et al.
[36] determined lower expression of miR-148a in 17
cases of poorly-differentiated HCC tissues relative to 15
cases of well-differentiated HCC tissues by using an
miRNA microarray analysis. In the current study, similar
trend was observed. In the poorly-differentiated group,
the relevant miR-148a level was 0.79 ± 0.48, slightly
lower than that in well-differentiated (0.88 ± 0.4) and
moderately-differentiated (0.9 ± 0.52) groups. However,
the differences did not reach a statistically significant
level. To our knowledge, no study has reported the re-
lationship between miR-148a expression and the clin-
ical TNM stages of HCC. In the present study, for the
Figure 1 Clinicopathological impact of miR-148a expression in hepatocellular carcinoma (HCC) tissues. Total miRNA was extracted from HCC
and their paired adjacent noncancerous liver tissues. MiR-148a expression was detected by using real time RT-qPCR and the relevant miR-148a level
was calculated as compared to the reference of miR-191 and miR-103 combination. Data were shown as mean ± SD. (A) Different liver tissues;
(B) Clinical TNM stages; (C) Metastasis; (D) Tumor capsular infiltration; (E) Tumor nodes. (F) The time-to-recurrence of high expression of miR-148a
(higher than the median level) was 61.47 ± 3.45 months, longer than those with low expression (50.56 ± 4.15); however, the difference was not
significant (P = 0.238).
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Figure 2 Receiver operator characteristic (ROC) curve of miR-148a
level in hepatocellular carcinoma (HCC). The area under the curve
(AUC) of miR-148a was 0.761 (95% CI 0.692 to 0.830, P< 0.001).
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stages III and IV was lower than that in stages I and II.
Furthermore, miR-148a expression was down-regulated
in the metastatic group compared with that in the non-
metastatic group. Additionally, miR-148a expression
was correlated with the status of tumor cell infiltration
into the capsule and the numbers of tumor nodes. The
status of tumor cell infiltration and tumor nodes gener-
ally reflects tumor invasion and metastasis and disease
deterioration. Zhang et al. [24] reported that miR-148a
decreased significantly in those HCC samples with por-
tal vein tumor thrombus. In this study, we also found
that in the subgroup with portal vein tumor embolus,
the miR-148a level (0.76 ± 0.53) was lower than that in
the subgroup without portal vein tumor embolus (0.92
± 0.48). Despite the fact that no statistically significant
association was found between miR-148a and portal
vein tumor embolus, the results from Zhang et al. [24]
and this current study point in the same direction, that
is that there is a noticeable relationship between miR-
148a and the infiltration of tumor cells, migration, inva-
sion and metastasis of HCC. Hence, it may be valuable
to clinically examine miR-148a expression for the pre-
diction of metastasis and deterioration of HCC. Next,
we also investigated the relationship between miR-148a
level and recurrence. The HCC patients with high ex-
pression of miR-148a had a longer time-to-recurrence
than those with low expression (61.47 ± 3.45 versus
50.56 ± 4.15); however, the difference is not significant.A larger cohort is needed to determine the correlation
between miR-148a and tumor recurrence in patients in
the future.
The mechanisms whereby miR-148a was reduced in
the advanced stages of HCC could be related to diverse
target genes and pathways involved. The epithelial-
mesenchymal transition (EMT) was reported to be
suppressed by miR-148a via targeting Met/Snail signal-
ing [24]. Yan et al. [36] further revealed that miR-148a
inhibits the metastasis of HCC by blocking EMT and
cancer stem cells (CSCs)-like properties through ef-
fects on the Wnt signaling. Both Gailhouste et al. [25]
and Long et al. [37] discovered a possible miR-148a-
DNA methyltransferase (DNMT) 1 regulatory circuit
in HCC. The aforementioned target genes and relevant
pathways can help to explain the role of miR-148a on
the metastasis and deterioration of HCC.
Conclusions
Together with previous reports, the current observations
strongly suggest that miR-148a acts as a tumor suppres-
sor miRNA, which plays a vital role in the tumorigenesis
and deterioration of human HCC. The current finding
may help to identify potential prognostic biomarkers for
HCC FFPE samples and provide a promising alterative
strategy for the therapeutic treatment of HCC patients.
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